This video demonstrates a model to study the development of myointimal hyperplasia after venous interposition surgery in rats.
Bypass grafting is an established treatment method for coronary artery disease. Graft patency continues to be the Achilles heel of saphenous vein grafts. Research models for bypass graft failure are essential for a better understanding of pathobiological and pathophysiological processes during graft patency loss. Large animal models, such as pigs or sheep, resemble human anatomical structures but require special facilities and equipment. This video describes a rat vein interposition model to investigate vein graft patency loss. Rats are inexpensive and easy to handle. Compared to mouse models, the convenient size of rats permits better operability and enables a sufficient amount of material to be obtained for further diverse analysis. In brief, the inferior epigastric vein of a donor rat is harvested and used to replace a segment of the femoral artery. Anastomosis is conducted via single stitches and sealed with fibrin glue. Graft patency can be monitored non-invasively using duplex sonography. Myointimal hyperplasia, which is the main cause for graft patency loss, develops progressively over time and can be calculated from histological cross sections.
Coronary artery diseases and their complications are among the leading causes of death worldwide. Current therapeutic strategies focus on re-establishing the blood flow, either by dilating the narrowed vessel or by creating a bypass. Coronary artery bypass grafting (CABG) using vein autografts was first described in 1968 and has been refined over the years. Apart from the revascularization of the left anterior descending coronary artery, saphenous vein conduits are most commonly used1. However, graft patency remains the Achilles heel of saphenous vein grafts (SVG). One year after surgery, graft patency is 85%, dropping to 61% after ten years2,3. Unveiling the pathophysiological mechanisms and causes of SVG patency loss is therefore an important task.
This video demonstrates a rat vein interposition model to investigate vein graft loss. The overall goals of this method are to explore the underlying pathobiological and -physiological processes during disease progression and to develop a suitable model for drug or therapeutic option testing. By transplanting the superficial epigastric vein into the arterial system, this model closely mimics the clinical setting of coronary artery bypass grafting. Surgical trauma, ischemia, and wall stress are important triggers of pathological vascular changes and are imitated in the model described.
Different models and species are available to investigate vein graft patency loss. Large animal models, such as pigs4, sheep5, dogs6, and monkeys7, resemble human vessel and anatomical structures and thus enable complex therapeutic strategies, such as bypass stenting or new surgical techniques, to be tested8. However, special housing, equipment, and staff are required. In addition, high costs and the need for an additional anesthetist during surgery impede their broader application. Small animals, including rats, are easy to handle, do not require special housing, and have manageable costs. Compared to mouse models9,10, rat models have the advantage of better operability and therefore less variability in the outcome. Rats are physiologically and genetically more similar to humans than mice11,12. In addition, most wild-type mice only develop limited myointima13, which make mouse models prone to type II errors. The histology of the main mouse veins, such as the inferior vena cava, only consists of a few cell layers and renders early evaluation difficult13. A further disadvantage is the small amount of tissue available for subsequent analysis after graft recovery.
The model described in this video is reproducible, inexpensive, and easy to perform, and it can be established quickly and reliably. It is especially suitable for evaluating expensive experimental therapeutic agents, such as viral vectors for gene therapy, in an economical fashion.
Animals received humane care in compliance with the Guide for the Principles of Laboratory Animals, prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health. All animal protocols were approved by the responsible local authority ("Amt für Gesundheit und Verbraucherschutz, Hansestadt (Office for Health and Consumer Protection) Hamburg").
1. Animal Care
2. Preparation of the Donor Rat
3. Preparation of the Recipient Rat
4. Duplex Sonography
NOTE: Use duxplex sonography to visualize blood flow non-invasively in rats14.
5. Histopathology
NOTE: Harvest and stain the vessel with Masson’s trichrome staining for morphometric analysis15.
6. Bioluminescence Imaging (BLI)
NOTE: The postoperative graft was tracked over time in vivo by measuring bioluminescent signal16.
The rat vein interposition model is suitable to study the development of myointima hyperplasia and vein graft failure. Animals recover well from the surgery and show excellent physical condition post-operation. Figure 1 shows the key surgical steps. After the skin incision along the linea inguinalis, the epigastric superficial vein and femoral artery are identified (Figure 1A). Harvesting of the graft should be performed carefully, without damaging the graft (Figure 1B), as this can lead to early graft failure and patency loss. After positioning the graft in the recipient animal (Figure 1C), anastomosis stitches are performed in the order shown in Figure 1D. The completed venous interposition graft appears pale (Figure 1E) and should become red and show pulsation after reperfusion (Figure 1F).
The successful integration of the vein into the femoral artery and graft patency after transplantation can be confirmed non-invasively using duplex sonography (Figure 2A). By transplanting the vein of a Luc-positive rat into a syngeneic Luc-negative rat, bioluminescence imaging can be used to monitor graft presence over time (Figure 2B).
Myointima hyperplasia develops progressively in the graft over time. Histological staining with Masson’s trichrome demonstrates myointima formation inside the internal elastic lamina (Figure 2C). The calculation of luminal obliteration, (dividing the cross-sectional area of the lumen by the area within the internal elastic lamina) revealed a gradual loss of graft patency from day 7 to day 28 post-surgery, thus confirming the reproducible dynamics of myointima hyperplasia in this rat model (Figure 2D).
Figure 1: Detailed Scheme of the Surgical Procedure. (A) Anatomy of the inguinal region. (B) Harvesting the epigastric superficial vein graft. (C) Placing the vein graft between the arterial stumps of the recipient animal. (D) Order of anastomosis stitches. (E) Site after the venous graft construction. (F) Site after the reperfusion of the venous interposition graft. Black arrows mark the epigastric superficial vein. The Scale bar = 5 mm. Please click here to view a larger version of this figure.
Figure 2: Characterization of the Animal Model. (A) Duplex sonography of a venous interposition graft immediately after transplantation (0d) and 28 days post-operation (28d). (B) BLI from Luc-positive grafts transplanted into Luc-negative rats at 0 days and 28 days after surgery. (C) Representative graft cross sections harvested after days 7, 14, 21, and 28 and stained with Masson’s trichrome. (Upper panel: the Scale bar = 400 µm; Lower panel: the Scale bar = 100 µm) (D) Luminal obliteration in percentage is calculated by dividing the new inner lumen from the former lumen. Intergroup differences were assessed by one-way analysis of variance (ANOVA) with Bonferroni’s post-Hoc test. p <0.01. The error bars are the standard deviation (SD). Please click here to view a larger version of this figure.
Supplemental File 1: Schematic Illustration of the Surgical Procedure. A vertical incision along the linea inguinalis is performed on the donor rat, exposing the inferior epigastric vein. Blood flow is stopped with two micro clamps, and a vein segment 0.5-1.0 cm long is harvested. In the recipient rat, a median femoral incision is performed, exposing the femoral vein, artery, and nerve. After clamping the femoral artery, a vessel segment is removed and replaced by the harvested vein graft. Please click here to view Supplemental File 1 (or right-click to download).
This video demonstrates a rat vein interposition model to investigate vein graft loss and to allow for the exploration of the underlying pathological processes and the testing of new drugs or therapeutic options.
Anesthesia is a crucial aspect of surgical procedures. A continuous inhalative anesthesia system is recommended, as this is a safe and easy method, especially during prolonged operations. This can be of great importance during the training phase, when the operation takes more than 1 hr.
With respect to the surgical procedure, it is critical not to damage the vein graft during harvest and implantation17. Gripping the adventitia of the vessel can prevent damage to the vein graft and avoid subsequent thrombus formation and graft failure. Graft patency can be determined immediately after vein graft construction through the observation of blood flow and of pulsation in the vein graft or distal artery, as well as through duplex sonography.
Another critical aspect of the procedure is to prevent the over-distension of the vein graft. Sudden exposure of the vein graft to the arterial pressure system leads to increased wall tension, subsequent over-distension, and changes in flow pattern. These are sources of thrombosis, anastomotic insufficiency, and early graft failure. Supporting the vein graft with fibrin glue can prevent uncontrolled ballooning and protect the intima and media from mechanical destruction. Absorbable collagen covers are an alternative to fibrin glue and can be used as perivenous covers18.
The most critical step within this protocol is undoubtedly the anastomosis between the vein graft and the artery. Care must be taken not to pierce the two walls of the vessel, as this will lead to the narrowing of the anastomosis, which may result in early failure of the graft. In addition, special attention must be paid to the localization of sutures. Congruency of the suture positions in the artery and vein ensures graft patency and prevents insufficiency. To facilitate this, sutures can be performed in the order shown in Figure 1D.
The degree of technical difficulty can be viewed as a limitation of the technique, because a novice must first become familiar with the microsurgical equipment and the small sizes of the anatomical structures. However, other models used exhibit the same difficulties, and we believe that this video will help novice surgeons to master this technique within a short time.
Numerous small animal models for venous graft failure have been described in the literature. However, most models only provide very small amounts of tissue for analysis13. An advantage of this method is the comparatively large amount of tissue that can be obtained. One graft can be divided into multiple parts and used for different assays, thereby reducing the number of experimental animals required.
Recent advances in zinc-finger nuclease technology enabled the generation of knockout rats19. By selecting suitable knock-out rats, graft patency loss can be studied in different disease conditions. For example, renin knockout rats can be utilized to study hypertension20. These genetic backgrounds can be combined with this animal model to glean information on the mechanisms of vein graft failure in different settings or on the impact of certain genes in the development of myointima hyperplasia.
In conclusion, the model described in this video is reproducible, inexpensive, and easy to perform, and it can be established quickly and reliably. Myointima hyperplasia, which is the main cause of vein graft failure, developed rapidly over four weeks, resulting in progressive luminal obliteration. Successfully tested treatment options in this model can be further confirmed in large animal models.
The authors have nothing to disclose.
The authors thank Christiane Pahrmann for her technical assistance. This study was funded by the Deutsche Stiftung fuer Herzforschung (F/28/14). D.W. was supported by the travel award from the International Society for Heart and Lung Transplantation. T.D. received the Else Kröner Excellence Stipend from the Else-Kröner-Fresenius-Stiftung (2012_EKES.04). S.S. received research grants from the Deutsche Forschungsgemeinschaft (DFG; DE2133/2-1, T.D. and SCHR992/3- 1, SCHR992/4-1, S.S.).
Rat LEW/Crl | Charles River | Stock number 004 | |
Rat LEW-Tg(Gt(ROSA)26Sor- 1 luc)11Jmsk |
Institute of laboratory animals, Kyoto University, Japan | NBPR rat number 0299 | http://www.anim.med.kyoto-u.ac.jp/NBR/ |
PFA 4% | Electron Microscopy Sciences | #157135S | 20% |
hair clipper | WAHL | 8786-451A ARCO SE | |
Forene | AbbVie | PZN 10182054 Art.Nr.: B506 | Isoflurane |
microsurgical clamp | Fine Science Tools | 18055-04 | Micro-Serrefine – 4mm |
clamp applicator | Fine Science Tools | 18056-14 | |
hair removal creme | Rufin cosmetic | 27618 | |
Povidone-Iodine | Betadine Purdue Pharma | NDC:67618-152 | |
10-0 Ethilon suture | Ethicon | 2814G | |
5-0 prolene suture | Ethicon | EH7229H | |
Rimadyl | Pfizer | 400684.00.00 | Carprofen |
Novaminsulfon | Ratiopharm | PZN 03530402 | Metamizole |
Heparin | Rotexmedica | PZN: 3862340 | 25.000 I.E./mL |
Xylocain 1% | AstraZeneca | PZN: 1137907 | Lidocain |
EVICEL | J&J Med.Ethicon Biosur | PZN 7349697 Art. Nr.:EVK01DE | fibrin glue |
NaCl 0,9% | B.Braun | PZN 06063042 Art. Nr.: 3570160 | |
Vevo 770 high-resolution in vivo micro-imaging system | VisualSonics | duplex sonography | |
Ecogel 100 ultrasound gel | Eco-med | 30GB | |
D-Luciferin Firefly, potassium salt | Biosynth | L-8220 | |
PBS pH 7,4 | Gibco | 10010023 | |
Xenogen Ivis 200 | Perkin Elmer | bioluminescence imaging | |
Weigerts iron hematoxylin Kit | Merck | 1.15973.0002 | Trichrome staining |
Resorcine-Fuchsine Weigert | Waldeck | 2.00E-30 | Trichrome staining |
Acid Fuchsin | Sigma-Aldrich | F8129-25G | Trichrome staining |
Ponceau S solution | Serva Electrophoresis | 33427 | Trichrome staining |
Azophloxin | Waldeck | 1B-103 | Trichrome staining |
Molybdatophosphoric acid hydrate | Merck | 1.00532.0100 | Trichrome staining |
Orange G | Waldeck | 1B-221 | Trichrome staining |
Light Green SF | Waldeck | 1B-211 | Trichrome staining |
Vitro-Clud | Langenbrinck | 04-0001 | |
Glacial Acetic Acid | Sigma-Aldrich | 537020 | |
37% HCl | Sigma-Aldrich | H1758 | |
Xylene | Th. Geyer | 3410 | |
Paraffin | Leica biosystems | REF 39602004 | |
Ethanol absolute | Th. Geyer | 2246 | |
Ethanol 96% | Th. Geyer | 2295 | |
Ethanol 70% | Th. Geyer | 2270 | |
Slide Rack | Ted Pella | 21057 | |
Staining dish | Ted Pella | 21075 | |
Bepanthen Eye and Nose ointment | Bayer | 1578675 | Eye ointment |